Design, Synthesis and Biological Evaluation of 3-Hydrazonoindolin-2-one Derivatives as Novel HIV-1 RNase H Inhibitors
Molecules · 2025
DOI: 10.3390/molecules30091868 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Yiying Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China. Hauptthemen laut MEDLINE: Drug Design, HIV-1, Ribonuclease H, Human Immunodeficiency Virus, Anti-HIV Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases.
Abstract (Originalsprache)
Targeting ribonuclease H (RNase H) has emerged as a highly promising strategy for treating HIV-1. In this study, a series of novel 3-hydrazonoindolin-2-one derivatives were designed and synthesized as potential inhibitors of HIV-1 RNase H. Notably, several of these derivatives displayed micromolar inhibitory activity. Among the compounds examined, the hit compound demonstrated potent inhibition of HIV-1 RNase H, boasting a Ki value of 2.31 μM. Additionally, the most potent compound of this general structure exhibited remarkable inhibitory activity, with Ki values of 0.55 μM. Through docking studies, the key interactions of this ligand within the active site of RNase H were uncovered. This novel chemical structure can be regarded as a prospective scaffold for the future development of RNase H inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China.
- Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai 200433, China.
- Henan Key Laboratory of Nanomedicine for Targeting Diagnosis and Treatment, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- Department of Life and Environmental Sciences, University of Cagliari, 09042 Monserrato, Italy.
- National Ph.D. Programme in One Health Approaches to Infectious Diseases and Life Science Research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, 27100 Pavia, Italy.
- Rega Institute for Meical Research, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium.
ORCID-Profile: Angela Corona, Laura Dettori, Enzo Tramontano, Christophe Pannecouque, Erik De Clercq, Shuai Wang
Förderung
- National Natural Science Foundation of China
- NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases
Zitieren
APA
Zhang, Y., Wang, R., Bu, Y., Corona, A., Dettori, L., Tramontano, E., Pannecouque, C., De Clercq, E., Wang, S., Meng, G., & Chen, F. E. (2025). Design, Synthesis and Biological Evaluation of 3-Hydrazonoindolin-2-one Derivatives as Novel HIV-1 RNase H Inhibitors. Molecules. https://doi.org/10.3390/molecules30091868
Vancouver
Zhang Y, Wang R, Bu Y, Corona A, Dettori L, Tramontano E, et al. Design, Synthesis and Biological Evaluation of 3-Hydrazonoindolin-2-one Derivatives as Novel HIV-1 RNase H Inhibitors. Molecules. 2025. doi:10.3390/molecules30091868
BibTeX
@article{Zhang2025,
author = {Zhang, Yiying and Wang, Rao and Bu, Yueyue and Corona, Angela and Dettori, Laura and Tramontano, Enzo and Pannecouque, Christophe and De Clercq, Erik and Wang, Shuai and Meng, Ge and Chen, Fen-Er},
title = {Design, Synthesis and Biological Evaluation of 3-Hydrazonoindolin-2-one Derivatives as Novel HIV-1 RNase H Inhibitors},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30091868}
}
EUVIMED